4fkaw4eqqo6zqmcrrg97 logo synapcell quadri (2)

SynapCell

3 Orders Completed
SAINT ISMIER, FR

About SynapCell

Founded: 2005 Type: Privately Held Size: 11-50 employees

SynapCell is a Brain-focused biotechnology company that provides drug developers with robust and unbiased endpoints on drug efficacy in vivo, at the preclinical step. We use quantitative, EEG-based methods to longitudinally monitor a drug effect on translational models, following clinical-like protocols. Our capabilities include dose-response studies, pharmacodynamics, biomarker identification and modulation, disease-modifying assays, model phenotyping, as well as phenotypic screening for lead selection and validation. Our expertise in Neuroscience covers Epilepsy, Parkinson's disease, Essential Tremors as well as information processing defects such as schizophrenia.


Since 2005, our returning customers in USA, Japan, Korea or Europe helped the company establish a unique reputation on the market and is the basis for long-lasting successful business partnerships.

Our Services (8)


ic

Parkinson's Disease Screening Platform

Price on request

TRANSLATIONAL BIOMARKERS OF PARKINSON'S DISEASE

We developed a full spectrum of translational EEG services to address Parkinson’s Disease using validated biomarkers of the disease at different stages. 

Get an A to Z evaluation of your compound on Parkinson’s Disease with BetaPark, the most translational EEG biomarker of PD, that is expressed in both PD patients and animal models, and GammaPark, related to L-DOPA induced Dyskinesia

LATE-ONSET : LEARN MORE 

L-DOPA-INDUCED DYSKINESIA : LEARN MORE 

In addition, we offer to combine GammaPark quantification with Abnormal Involuntary Movement (AIM) scoring. Three types of AIMs can be assessed during a chronic GammaPark study: 

- Axial (Ax): contralateral torsion of the neck and body.

- Limb (Li): involuntary and repeated movement of the contralateral forelimb. 

- Orolingual (OI): contralateral chewing, tongue sticking out. 

- Correlate behavioral scoring with the translational power of GammaPark in a single study 


Parkinson's disease (PD) CNS/Neurology in vivo EEG compound screening Compound testing L-DOPA rats Mice CNS/Neurology Show 10 more tags Show less

ic

Animal Electroencephalography (EEG)

Price on request

Technical capabilities for preclinical efficacy testing


Stereotaxic surgery on mice and rats

    - Cortical and subcortical electrodes implantation for the recording of electrophysiological activities (electrocorticogram and local field potentials).

    - Ability to access any brain structure of interest.


“In-house” developed algorithms

    - Development of EEG analysis tools in a Matlab® environment

    -Analysis algorithms of spontaneous and evoked EEG activities developed “in-house” by SynapCell.


Large flexibility in electrophysiological recording designs and set-ups

    -Depth electrodes (LFP)

    -Surface electrodes (ECoG)

    -Telemetric / Tethered recordings

    - Electrophysiological set-up (hardware) design.


Clinical-like protocols: Adapted study design

    -Crossover/Blinded

    -Acute

    -Chronic/Sub chronic.


qEEG protocols

    -Frequency spectrum analysis

    -Multisite coherence

    -Sleep/Wake states

    -Phase Amplitude Coupling (PAC).


Auditory-evoked protocols

    -Auditory evoked potential (ERP, AERP)

    -Auditory Steady-State Response (ASSR)

    -Sensory Gating

    -Positive and Negative deflections analysis (amplitude, latencies)

    -Inter-trial coherence (ITC).

    -Detailed analysis and reporting, all studies including:

    -Expert data analysis and interpretation

    -Statistical analysis using GraphPad Prism®

    -Preliminary results presentation

    -Full comprehensive report.


LEARN MORE

EEG ASSR AERP SWD qEEG in vivo ERP EEG CNS/Neurology Epilepsy Parkinson's disease (PD) cognition Movement disorders Phenotyping Data analysis Comprehensive report Biomarkers Show 17 more tags Show less

ic

Electroencephalography (EEG) Data Analysis

Price on request

Your data deserve the best. Our analysis capabilities include deep-learning and proprietary algorithms that have common grounds with patients EEG analysis.


Your data will benefit from the combined power of the Cue® analysis platform and SynapCell’s expertise to save time and resources on EEG data analysis.


Beyond data analysis, you will get a full detailed report and personnalized presentation of the results as well as recommendations from our experts.

CNS/Neurology EEG Epilepsy Parkinson's disease (PD) Movement disorders CNS/Neurology Data analysis Comprehensive report Show 8 more tags Show less

ic

Biomarkers

Price on request

EEG BIOMARKERS PROVIDE OBJECTIVE MEASURES OF BRAIN [DYS]FUNCTION. AT THE SOURCE.


Unique on the market, our EEG Biomarker approach delivers smooth human-rodent translation, high reproducibility levels and robust endpoints, particularly well-suited to evaluate your compounds effects with no bias.

AERP / ASSR : psychiatric or cognitive disorders

SWD : Absence epilepsy

HPD : Mesio-Temporal Lobe Epilepsy

BetaPark : Parkinson's Disease

GammaPark : L-DOPA induced Dyskinesia

Tremor Band : Essential Tremor

LEARN MORE

CNS/Neurology psychatric disorders in vivo EEG ASSR AERP Mice rats CNS/Neurology Parkinson's disease (PD) Epilepsy Essential tremor Movement disorders Biomarker Identification Phenotyping Show 15 more tags Show less

ic

Lead Identification and Validation

Price on request

From HIT ID to Lead validation


The MTLE model can be useful for several applications, including the screening of a small library of compounds, performing dose-response studies or assessing the disease-modifying potential of your compound on epileptogenesis (anti-epileptogenic effect).


It is possible to conduct dose-response studies immediately after a screening setting (HIT ID and Lead selection) or in a brand new setting in the MTLE mouse or GAERS rat.


We typically propose to assess the selected compounds at 3 doses vs positive control and vehicle and monitor its pharmacodynamics in vivo, on freely-moving animals, and longitudinally.


In particular, we offer to:


- Evaluate the potentiating or synergistic effects of an AED when combined to other drugs

- Identify the most effective drug associations

- Shape your project according to your compound PK

- Combine a MTLE study (focal epilepsy) with a GAERS study (generalized epilepsy) to derisk your compounds, identify seizure-aggravating effects and more importantly, align your preclinical strategy with your clinical roadmap to validate your AED.

SynapCell holds the World-exclusive license rights on the GAERS model of absence generalized epilepsy and offers more than 15 years’ experience with the MTLE mouse model of focal drug-refractory epilepsy.


Epilepsy in vivo EEG Mice rats MTLE GAERS CNS/Neurology compound screening Biomarkers Show 10 more tags Show less

ic

Hit to Lead and Lead Optimization

Price on request

How about identifying the therapeutic potential of preclinical drug candidates in vivo in a predictive fashion?


SynapCell offers the possibility to screen small libraries of compounds to highlight their anti-epileptic or pro-epileptic effect using our non-convulsive and translational MTLE or GAERS models. Your compounds properties will be evaluated by our non-biased, dynamic EEG platform and scientific expertise in epilepsy.

This setting allows for: 

- quick turnaround

- reliable identification of compounds with the best anti-epileptic potential  

- smooth preclinical to clinical translatuion of the results  

- Hit to lead selection  

- chaining with our Lead validation setting, in which the selected compounds can be deeper characterized with a full crossover, dose-response paradigm.  

We typically propose to assess the selected compound at 3 doses vs positive control and vehicle and monitor its pharmacodynamics in vivo, on freely-moving animals, and longitudinally.

SynapCell holds the World-exclusive license rights on the GAERS model of absence generalized epilepsy and offers more than 15 years’ experience with the MTLE mouse model of focal drug-refractory epilepsy.

Epilepsy in vivo freely moving EEG Mice rats CNS/Neurology compound screening Biomarkers Show 9 more tags Show less

ic

In vivo Phenotypic Screening

Price on request

How about identifying the therapeutic potential of preclinical drug candidates in vivo in a predictive fashion?

SynapCell offers the possibility to screen small libraries of compounds to highlight their anti-epileptic or pro-epileptic effect using our non-convulsive and translational MTLE or GAERS models. Your compounds properties will be evaluated by our non-biased, dynamic EEG platform and scientific expertise in epilepsy. 

This setting allows for: 

- quick turnaround 

- reliable identification of compounds with the best anti-epileptic potential 

- smooth preclinical to clinical translatuion of the results 

- Hit to lead selection 

- chaining with our Lead validation setting, in which the selected compounds can be deeper characterized with a full crossover, dose-response paradigm. 

We typically propose to assess the selected compound at 3 doses vs positive control and vehicle and monitor its pharmacodynamics in vivo, on freely-moving animals, and longitudinally.

SynapCell holds the World-exclusive license rights on the GAERS model of absence generalized epilepsy and offers more than 15 years’ experience with the MTLE mouse model of focal drug-refractory epilepsy.

CNS/Neurology Epilepsy EEG Mice rats CNS/Neurology in vivo AAV testing Phenotypic screening Phenotyping compound screening Show 11 more tags Show less

ic

Epilepsy & Seizure Animal Models

Price on request

in vivo anti-epileptic effect - Generalized Absence epilepsy


Novel Anti-Epileptic Drugs (AEDs) are required to be effective on both focal (partial) epilepsy and generalized (absence) seizures. Translational and non-convulsive animal models are available at SynapCell for both of the applications above, so you can align your preclinical to clinical roadmap with the support of an experienced partner.

Genetic absence epilepsy rat from Strasbourg (GAERS) is a selectively inbred strain of Wistar rats displaying spontaneous spike-and-wave discharges (SWD). The GAERS has become a reference model for absence epilepsy for more than 30 years, since these rats present behavioral, electrophysiological and pharmacological features of human absence seizures.

The pharmacology of the GAERS model is indeed just like the human’s. For instance, valproate, ethosuximide and levetiracetam are equally effective in both human patients and GAERS.

SynapCell World-exclusive, the GAERS is a key asset to validate new Anti-Epileptic Drugs (AED) and derisk potential seizure-aggravating effect of any drug tested.


Epilepsy in vivo EEG SWD GAERS rats CNS/Neurology Compound testing compound screening Biomarkers Show 10 more tags Show less

Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.
AE

Alexis Evrard

Head of Operations
HG

Hedi Gharbi

EU/APAC Sales - Head of Marketing
HM

Hugo Monchal

International Sales Engineer
EM

Emilie Moury

Key Account Manager

FileType/PDF Created with Sketch. Duveau et al Neurochem Res 2017 MTLE.pdf

Click to Download

FileType/PDF Created with Sketch. Duveau_et_al-2016-CNS_Neuroscience__Therapeutics.pdf

Click to Download

FileType/PDF Created with Sketch. Duveau_et_al-2019-CNS_Neuroscience__Therapeutics.pdf

Click to Download

FileType/PDF Created with Sketch. Epilepsy Programs at SynapCell.pdf

Click to Download

FileType/PDF Created with Sketch. SynapCell-FAQ.pdf

Click to Download

SynapCell has not received any reviews.

SynapCell has not received any endorsements.